An Expert View from Neelam Patel, chief executive of MedCity, a not-for-profit that serves as the life sciences cluster organization for London. 2 May 2022
Rare diseases powerhouse Alexion was last year acquired for $39 billion by the Anglo-Swedish pharma major AstraZeneca, becoming part of one of big pharma’s most 22 April 2022
A Feature on the Japanese pharma market from Patrick Branch, a Partner in LEK's Tokyo office and a member of the firm’s Life Sciences practice. 8 April 2022
In recent years there has been an explosion of digital tools in the life sciences.but as with everything in pharma and biotech.their value hinges on the strengt 5 April 2022
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news